SS-31 (Elamipretide)

The 2025 review describes its sequence as D-Arg–Dmt–Lys–Phe-NH₂. Naming conventions can vary between publications, so identify the exact compound and test article in each source rather than treating a familiar label as batch-specific verification.

This opening file records published identity and research context. Its conceptual artwork is not an exact molecular structure, and a literature designation alone does not establish the identity or analytical quality of any material.

• Reported identity: elamipretide / SS-31
• Reported class: synthetic tetrapeptide
• Check source-specific nomenclature and test-article characterization

The review describes cardiolipin interaction as a key part of the proposed model. Keep that mechanistic framing tied to the cited evidence: a conceptual illustration is not a measured binding pose, and downstream effects should not be inferred from an adjacent observation alone.

When assessing a mechanism claim, check the experimental preparation, the interaction or endpoint directly measured, the controls, and whether the cited experiment tests the proposed link rather than summarizing it from prior work.

• Cardiolipin is the principal interaction discussed in the review
• Membrane organization and bioenergetics are research topics in the literature
• The artwork does not depict confirmed binding or measured pathway output

Campbell and colleagues reported a study in aged mice examining skeletal-muscle mitochondrial energetics and redox-related measures. The paper describes in-vivo spectroscopy alongside tissue and molecular analyses, including redox proteomics. Its methods and findings belong to that specific model and experimental design.

Keep measured signals distinct from interpretation: an energetic measure, a protein-expression result, and a redox-proteomic observation are not interchangeable endpoints. Read the original methods, comparator groups, and limitations before drawing a broader conclusion.

• 2019 study: aged-mouse experimental model
• Multiple methods examined distinct mitochondrial and redox endpoints
• Model, assay, comparator, and endpoint define the scope of interpretation

The 2019 mouse study is a preclinical record with a defined model and measurement strategy. The 2025 review summarizes several clinical-development programs as a separate body of literature. Those records answer different questions and should not be represented as a single head-to-head comparison.

A useful comparison names the study type, model or population, comparator, endpoint, and source. The conceptual image separates evidence lanes to emphasize method boundaries; it does not report outcomes or establish that different studies are directly comparable.

• Preclinical model evidence and clinical-program reviews are distinct record types
• Compare methods and endpoints before comparing conclusions
• Cross-study context is not a direct head-to-head result

The reviewed mechanism centers on cardiolipin and mitochondrial research, while individual studies examine bounded experimental questions. A review is a synthesis, not a substitute for primary methods; preclinical observations do not by themselves settle questions raised by other research settings.

A careful evidence map checks compound identity, study design, controls, analytical validity, replication, endpoints, and how well each conclusion is supported by its cited source. Unknowns should remain visible as open questions rather than being filled in by illustrative artwork or inference.

• Reported identity does not verify a specific test article
• Mechanistic proposals and measured outcomes are separate evidence layers
• Methods, replication, and study context constrain interpretation
• The illustration marks open questions; it is not data or a prediction